TICKERNERD
Menu
CHECHEHealthcare · Medical Care Facilities

CHE Stock Forecast: Chemed Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$548
+2.63% on the day

The 5 Wall Street analysts covering Chemed Corp. hold a median 12-month price target of $620 — +13.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$6.9B
Ticker Nerd rank
83/ 100
Median analyst target
$620
Analysts covering
5
Revenue$657.5M+1.6% y/y
Operating income$84.6M
Net income$66.3M
Free cash flow$71.1M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.7%
1M
+7.9%
YTD
+28.5%
1Y
+25.4%
From 52W high
−0.8%
From 52W low
+49.0%
$368
$552
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CHE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Chemed Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
83/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Revisions
90
Quality
85
Momentum
68
Growth
67
Value
63
Issuance
53
Accruals
49
Size
18

Volatility (93): The share price has been relatively steady.

Accruals (49): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CHE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CHE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$350$400$450$500$550$600$650$700Jan 26Apr 26Jul 26Oct 26CHEHigh $675Median $620Low $580

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $580Median $620High $675

The green dot is the last close — the median target sits +13.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 Oct 2026OppenheimerMaintainsOutperform$590 → $625
29 Oct 2026RBC CapitalMaintainsSector Perform$548 → $585
29 Oct 2026UBSMaintainsBuy$650 → $675
28 Oct 2026JefferiesUpgradeBuy$520 → $620
25 Sept 2026UBSInitiatesBuy$650
25 Sept 2026UBSInitiatesBuy—
31 July 2026OppenheimerMaintainsOutperform$500 → $590
31 July 2026OppenheimerMaintainsOutperform—
30 July 2026RBC CapitalMaintainsSector Perform$436 → $548
30 July 2026RBC CapitalMaintainsSector Perform—
9 July 2026B of A SecuritiesMaintainsNeutral$450 → $510
9 July 2026B of A SecuritiesMaintainsNeutral—
27 Apr 2026RBC CapitalMaintainsSector Perform—
27 Feb 2026OppenheimerMaintainsOutperform—
27 Feb 2026RBC CapitalDowngradeSector Perform—
22 Jan 2026JefferiesDowngradeHold—
10 Nov 2025RBC CapitalMaintainsOutperform—
10 Sept 2025B of A SecuritiesMaintainsBuy—
2 Sept 2025JefferiesUpgradeBuy—
31 July 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CHE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CHE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Chemed Corp. returned +25.4% against +14.8% for the S&P 500, dividends included.

CHE vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26CHES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CHE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.2%
Analysts raising
0
Analysts cutting
1
Fundamentals

Chemed Corp. (CHE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.6×

Cheaper than 29% of US stocks

Price / sales
2.6×

Cheaper than 44% of US stocks

Price / book
8.0×

Cheaper than 11% of US stocks

EV / EBITDA
16.6×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
10.6%

Higher than 54% of US stocks

Earnings growth (YoY)
11.5%

Higher than 51% of US stocks

Gross margin
32.8%

Higher than 38% of US stocks

Operating margin
15.1%

Higher than 73% of US stocks

Net margin
10.6%

Higher than 70% of US stocks

Returns & dividend
Return on equity
29.1%

Higher than 87% of US stocks

Return on assets
14.3%

Higher than 96% of US stocks

Dividend yield
0.5%

Higher than 66% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Chemed Corp. (CHE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Chemed Corp. has a market value of $6.9B and an enterprise value of $7.4B.

  • Revenue in the twelve months to 31 Mar 2026: $2.5B. The latest quarter grew 10.6% year on year.

  • Net income over the same four quarters: $259.8M, a 10.2% net margin.

  • Diluted earnings per share, trailing twelve months: $18.35.

  • Free cash flow in the twelve months to 31 Mar 2026: $377.1M, after $50.5M of capital spending.

  • Chemed Corp. spent $588.3M on share buybacks and $32.5M on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 13.1M.

  • Trailing P/E: 25.6×; forward P/E: 19.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.52%, paying out 12% of earnings.

  • Chemed Corp. employs 15,811 people — $161K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

CHE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
CHEChemed Corp.$6.9B83
PACSPACS Group, Inc.$8.0B73
CONConcentra Group Holdings Parent, Inc.$5.6B93
LFSTLifestance Health Group, Inc.$5.5B92
ENSGThe Ensign Group, Inc.$10.9B65
OPCHOption Care Health, Inc.$5.0B92
UHSUniversal Health Services, Inc.$11.6B56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Chemed Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CHE news & analysis

Why Chemed (CHE) is a Top Value Stock for the Long-Term

Zacks Investment Research · 2 Nov 2026positive

Zacks Investment Research’s article describes Zacks Style Scores, a feature of its Zacks Premium research service, as a tool for finding stocks across value, growth, and momentum investing styles. The headline characterizes Chemed (CHE) as a top value stock for the long term.

Why it matters — CHE watchers may find the article’s value-oriented framing relevant when reviewing Zacks’ research on the company.

Chemed Corporation to Present at the UBS 2026 Global Healthcare Conference

GlobeNewsWire · 2 Nov 2026neutral

Chemed Corporation announced it will present at the UBS 2026 Global Healthcare Conference on November 9, 2026, at approximately 8:45 a.m. ET. The presentation will take place at PGA National Resort in Palm Beach Gardens, Florida.

Why it matters — The announcement provides CHE watchers with the scheduled time and location of the company’s conference presentation.

What Chemed (CHE) Said on Its Q3 Earnings Call

MarketBeat · 29 Oct 2026positive

Chemed reported higher third-quarter revenue and adjusted earnings. Growth at its VITAS hospice business offset margin pressure at Roto-Rooter from customer-acquisition and fuel costs.

Why it matters — CHE watchers can assess how VITAS growth and Roto-Rooter cost pressures contributed to the company’s quarterly results.

Chemed Corporation (CHE) Q3 2026 Earnings Call Transcript

Seeking Alpha · 28 Oct 2026neutral

Chemed Corporation held its third-quarter 2026 earnings conference call on October 28, 2026. The excerpt lists company and conference-call participants and provides the operator’s opening remarks.

Why it matters — The excerpt confirms the Q3 2026 call took place but contains no financial results or business updates for CHE watchers to assess.

Chemed (CHE) Tops Q3 Earnings and Revenue Estimates

Zacks Investment Research · 27 Oct 2026positive

Chemed reported third-quarter earnings of $6.75 per share, above the Zacks Consensus Estimate of $6.39. Earnings were $5.27 per share in the year-ago quarter.

Why it matters — The results show Chemed exceeded the cited earnings estimate and reported higher per-share earnings than a year earlier.

FAQ

Frequently asked questions about CHE stock

What is the CHE stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Chemed Corp. have a median 12-month price target of $620, with estimates ranging from $580 to $675. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CHE stock a buy right now?

Of the 5 analysts covering Chemed Corp., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Chemed Corp. 83 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CHE?

As at 4 Nov 2026, Chemed Corp. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will CHE stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +13.2% from the last close, and Ticker Nerd's factor model ranks Chemed Corp. 83 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CHE stock forecast for 2030?

No analyst covering Chemed Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $580 to $675 over the next 12 months.

How has CHE stock performed over the past year?

Chemed Corp. returned +25.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Chemed Corp. do?

Chemed Corp. is a diversified holding company focused on healthcare and essential home services.

What is the latest news on CHE?

The most recent item we track (Zacks Investment Research, 2 Nov 2026): "Why Chemed (CHE) is a Top Value Stock for the Long-Term". Zacks Investment Research’s article describes Zacks Style Scores, a feature of its Zacks Premium research service, as a tool for finding stocks across value, growth, and momentum investing styles. The headline characterizes Chemed (CHE) as a top value stock for the long term.

Company

About Chemed Corp.

Chemed Corp. is a diversified holding company focused on healthcare and essential home services. Its operations are organized around two core segments: VITAS, which provides hospice and palliative care through a multidisciplinary network of clinicians and caregivers, and Roto-Rooter, which delivers plumbing, drain cleaning, excavation, and water restoration services to residential and commercial customers. Chemed Corp. serves patients, families, homeowners, businesses, and property managers across the United States, combining end-of-life care services with maintenance and emergency repair solutions. The company’s business model centers on operating specialized service brands with distinct customer needs and market dynamics, giving it a unique position in both healthcare services and home repair markets.

CEO Mr. Kevin J. McNamara · 15,811 employees · United States · https://www.chemed.com